Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicountry, Multicentre, Non-interventional, Prospective Study to Determine the Prevalence of EGFR Mutations in Patients With Early-stage, Surgically Resected, Non-squamous, Non-small Cell Lung Cancer

NCT04742192 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04742192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04742192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicountry, Multicentre, Non-interventional, Prospective Study to Determine the Prevalence of EGFR Mutations in Patients With Early-stage, Surgically Resected, Non-squamous, Non-small Cell Lung Cancer
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
March 4, 2021
Completion date
November 30, 2022
Enrollment
601 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer